Withdrawal Notice
This paper was originally published in Oncotarget Advance Online Publications on 01/03/2018.In compliance with Oncotarget's withdrawal policy, the paper was withdrawn in its entirety. It will not appear in Oncotarget internal or any external indexes or archives.
Research Papers:
Autoimmune response of p53 and its regulator MDM2 in patients with hepatocellular carcinoma
Li-Ping Dai1,2,3,*, Ji-Tian Li3,*, Xiao Wang1,2,3 and Jian-Ying Zhang1,2,3
1 Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China
2 Henan Key Laboratory for Tumor Epidemiology, Zhengzhou University, Zhengzhou, Henan, China
3 Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX, USA
* Li-Ping Dai and Ji-Tian Li contributed equally to this work
Correspondence to:
Jian-Ying Zhang, email: [email protected]
Li-Ping Dai, email: [email protected]
Keywords: hepatocellular carcinoma (HCC); autoantibody; MDM2; p53
Received: July 13, 2017 Accepted: October 30, 2017 Epub: January 03, 2018
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23906